If GDT has an approved successful DES, and is not required to divest itself of this product line as part of a J&J aquisition, what do you think would be the short and long term impact on market share for both of these types of DES? Would this not be a greater threat to BSX than the results of the J&J patent infringement law suit?
You bet. GDT Vision stent beats the c--p out of either Express or Liberte. This head to head trial is another "shot on goal" as Dollens was fond of saying to demonstrate a statistical superiority of an 'imus stent over a taxol stent. If they show Vision with everolimus superior to Taxus, BSX market share (with or without JNJ merger) will hit low single digits. i.e., more deliverable AND better clinical outcomes. It's only a matter of time as this (BSX) ship slowly sinks. Next generation Cypher will start trials soon as well and be better than either Vision or Taxus Liberte.
hold the phone, until the data is in, non bias, peer reviewed, you are guessing on the results and hoping that the GDT stent will be superior. You sound like a short seller. I believe in a head to head fair comparison, Taxus will be superior.